alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 76–100 of 121 studies in Vascular contributions published 2025 (page 4 of 5) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 121 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,851 studies have no institution on record and are not counted here.

What “Vascular contributions” covers

Vascular contributions — How blood vessel health, small-vessel disease and stroke risk contribute to dementia and cognitive decline.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Burden of dementia following stroke subtypes: a study integrating the GBD database and Mendelian randomization

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Journal of Stroke and Cerebrovascular Diseases 2025-08-27

The relative risk of dementia following cerebral hemorrhage ( relative risk(RR):3.02[1.17-7.78],P<0.001 ) was higher than that of cerebral infarction (RR: 2.07[1.47-2.96], P<0.001). 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Monogenic causes of cerebral small vessel disease- models for vascular cognitive impairment and dementia?

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current Opinion in Psychiatry 2025-01-22

Recent advancements in molecular biomarkers and therapeutic options for Alzheimer's disease have brought into focus the need for greater progress in the second most common cause of dementia, vascular cognitive impairment and dementia (VCID). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

FDG-PET anterior cingulate cortex hypometabolism as a marker of cerebral small vessel disease in Alzheimer's and vascular cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cerebral Circulation - Cognition and Behavior 2025-01-01

• Anterior cingulate cortex (ACC) hypometabolism is a non-specific finding in many brain disorders. • ACC hypometabolism was more common in vascular cognitive impairment and dementia (VCID) than Alzheimer dementia (AD). • ACC hypometabolism correlated with cerebral small vessel disease markers. • ACC hypometabolism may be associated with motor stereotypies in VCID. • FDG-PET patterns of hypometabolism may identify vascular contributions to cognitive impairment The anterior cingulate cortex (ACC) is an important hub in the executive and salience networks. 2 key findings →

Participants: 379 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Genetic Downregulation of Interleukin‐6 Signaling and Arteriolosclerotic Cerebral Small Vessel Disease: A Drug Target Mendelian Randomization Analysis

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of the American Heart Association 2025-11-03

variants) was not associated with small vessel stroke (odds ratio [OR], 1.02 [95% CI, 0.95-1.10]), magnetic resonance imaging-confirmed lacunar stroke (OR, 0.95, [95% CI, 0.81-1.11]), nonlobar intracerebral hemorrhage (OR, 1.04 [95% CI, 0.72-1.50]), or vascular dementia (OR, 1.09 [95% CI, 0.95-1.25]). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood deprivation and midlife cognition: Evidence of a modifiable vascular pathway involving health behaviors and cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-11-01

Neighborhood deprivation was associated with poorer cognition (r = 0.36, p < 0.001), greater prevalence of modifiable risk factors (r = 0.36, p < 0.001), and greater SVD burden (β = 0.18, p = 0.008). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Analysis of brain dynamics changes in patients with cerebral small vessel disease-related cognitive impairment based on electroencephalogram microstates

✓ Peer-reviewed alzhub usefulness score 41 out of 100. European journal of medical research 2025-08-21

1. Neuropsychological assessments indicated that the CSVD group scored significantly lower than the HC group in general cognitive level, memory, visuospatial ability, executive function, and language function (p < 0.05). 2. 5 key findings →

Participants: 40 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Risk of stroke associated with risperidone in dementia with and without comorbid cardiovascular disease: population-based matched cohort study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The British Journal of Psychiatry 2025-10-09

In the overall cohort (28 403 risperidone users and 136 324 mtatched controls), risperidone was associated with increased risk of stroke (adjusted hazard ratio: 1.28; 95% CI: 1.20-1.37). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effects of regional white matter hyperintensities and β-amyloid on domain-specific cognition and progression to dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Brain and Cognition 2025-06-24

White matter hyperintensities (WMHs) and cerebral β-amyloid (Aβ) have been characterized as clinically significant biomarkers associated with greater cognitive decline and incidence of Alzheimer's Disease (AD) dementia. 3 key findings →

Participants: 523 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The White Matter Hyperintensity Shape and Brain Clearance (WHIMAS) Study for Identification of Novel 7T Magnetic Resonance Imaging Markers of Cerebral Small Vessel Disease: Protocol for a Cross-Sectional Study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. JMIR Research Protocols 2025-12-04

Patient inclusion started in January 2023, and study enrollment of patients is expected to finish in the second quarter of 2027, whereas the main results are expected to be published in the first quarter of 2028. 5 key findings →

Design: cross-sectional Participants: 50 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Harmonization Remains Unresolved: The Case of White Matter Hyperintensity Using ComBat And Deming Regression

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

Using a unique dataset of the same participants scanned close in time on different scanner and protocols, we found that (1) MMD measurements were useful to test the need/improvement due to harmonization; (2) ComBat was not substantially better at creating compatible distributions between scanner vendors than Deming regression, and both were sometimes inadequate. 4 key findings →

Participants: 53 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The burden of stroke, ischaemic heart disease, and dementia in Africa, 1990–2021: an ecological analysis of the Global Burden of Disease 2021

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet Global Health 2025-06-25

In Africa in 2021, 17·3 (95% UI 15·5-19·2) million DALYs were lost due to strokes, 17·6 (15·5-19·6) million were lost due to ischaemic heart diseases, and 1·8 (0·8-4·0) million were lost due to dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Emerging biomarkers and frontier therapies: unveiling the role of endothelial dysfunction in cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in Neurology 2025-07-11

Cerebral small vessel disease (cSVD), a major contributor to stroke, cognitive decline, and vascular dementia, accounts for around 25% of ischemic strokes and significantly impacts age-related neurological disability. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Endothelial progenitor cells and cerebral small vessel disease in APOE4 carriers

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Cerebral Circulation - Cognition and Behavior 2025-01-01

• APOE4 carriers exhibit cerebrovascular dysfunction. • Endothelial progenitor cells (EPC) represent cell populations involved in facilitating vascular repair. • In APOE4 carriers, EPC colony count is associated with cerebral small vessel disease. • EPC colony count may indicate activation of mechanisms which protect cerebrovascular function in APOE4 carriers prior to the development of cognitive decline. 4 key findings →

Participants: 109 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Incidental covert cerebral small vessel disease: Detection and management

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Advanced Neurology 2025-01-16

Cerebral small vessel disease (CSVD) is one of the most common vascular diseases of the brain, primarily diagnosed using magnetic resonance imaging biomarkers. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia Translational Research & Clinical Interventions 2025-01-01

On March 12–14, 2024, the National Institute on Aging (NIA) together with the National Institute of Neurological Disorders and Stroke (NINDS) led a workshop exploring clinically meaningful changes in the context of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD) clinical trials ( https://www.nia.nih.gov/research/dbsr/workshops/clinically‐meaningful‐outcomes‐ad‐adrd‐trials ). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association between Serum Levels of Interleukin-6 and Stroke, Cardiovascular Events, and Alzheimer’s Disease Dementia

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Atherosclerosis and Thrombosis 2025-06-05

During a median follow-up period of 4.6 years, stroke, MACEs, and AD dementia occurred in 24, 36, and 21 patients, respectively. 5 key findings →

Design: post-hoc analysis Participants: 1,011 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pharmacotherapy for Poststroke Cognitive Impairment and Poststroke Cognitive Impairment With Dementia: A Review

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Stroke Research and Treatment 2025-01-01

Poststroke cognitive impairment (PSCI) refers to any level of cognitive decline occurring after a stroke, ranging from mild to severe impairments, while PSCI with dementia describes a more severe form where the cognitive decline significantly affects daily functioning and meets the clinical criteria for dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events